The iron deficiency specialist will absorb its co-commercialisation partner's sales force and retain all US gross profit from ACCRUFeR, paying Viatris a royalty instead of a profit share.

The iron deficiency specialist swung to an operating profit in the first half and remains on track for full-year operating profitability, despite Medicaid disruption in New York.

Chief executive Anders Lundstrom said the company was "pleased with the significant growth in our largest business segment, commercial, which represents two-thirds of total revenue, alongside strong overall prescription growth."

Peer-reviewed publication confirms ferric maltol's safety and effectiveness in children as young as two months, supporting plans to extend ACCRUFeR into younger age groups.

Shield Therapeutics reported Q1 2026 net revenue of $18m and positive EBIT of c.$2.5m, driven by a $7.9m development milestone and 54% growth in its ACCRUFeR® franchise.

Shield Therapeutics has confirmed first patient enrollment by its Japanese partner MEDLEAP Pharma in an exploratory Phase II trial of ACCRUFeR (ferric maltol) for pulmonary arterial hypertension, a study intended to support a planned Phase III in Japan.